Resveratrol: A medical drug for acute pancreatitis

Zhen-Hua Ma, Qing-Yong Ma

Zhen-Hua Ma, Qing-Yong Ma, Division of General Surgery of First Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China
Correspondence to: Dr. Zhen-Hua Ma, PhD, Division of General Surgery of First Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China. mazhenhua2005@163.com
Telephone: +86-29-85324009 Fax: +86-29-85323536
Received: 2004-07-23 Accepted: 2004-11-25

Abstract
Accumulating evidence demonstrates that resveratrol, a natural polyphenolic compound extracted from plants, inhibit inflammation when administered. It has direct effects on suppression of platelet coagulation and cytokines production in many experimental models. Because microcirculation occlusion and cytokines over-production is involved in many diseases such as acute pancreatitis (AP), the discovery of resveratrol as platelet and cytokines inhibitors has shed light on the treatment of AP, which still has significant mortality and morbidity. It is anticipated that this natural polyphenol could serve as a therapeutic compound in managing AP through different pathways.

© 2005 The WJG Press and Elsevier Inc. All rights reserved.

Key words: Resveratrol; Drug; Acute pancreatitis

Ma ZH, Ma QY. Resveratrol: A medical drug for acute pancreatitis. World J Gastroenterol 2005; 11(21): 3171-3174
http://www.wjgnet.com/1007-9327/11/3171.asp

INTRODUCTION
Acute pancreatitis (AP) is an emergent and severe disease of peptic system and the plasma amylase and lipase values are elevated in most patients[1]. There are different factors leading to AP. However, if dangerous factors are immediately cleared off and do not produce the progressive injury, the pancreatic structure and function can recover to normal. On the contrary, pancreas would encounter injury if the life-threatening factors could not be controlled. For example, severe AP can change the structure of pancreatic duct and finally lead to chronic obstructive pancreatitis. Currently, the diagnosis and management of AP have already become the hot topic of research and has made great progress.

In 1940, Dr. Takaoka extracted resveratrol from plant and found its chemical structure as 3,4',5-trihydroxy-trans-stibene[2]. In recent years, resveratrol has already been found in about 70 plant species. The highest concentration of resveratrol (50-100 µg/g) is found in grape skins. Many biological characters of resveratrol have already been proved, including anti-inflammatory, anti-oxidation, chemopreventive effects, and inhibition of platelet aggregation[3-5]. From the already admitted characters of resveratrol and the factors leading to the occurrence of AP, we can draw a hypothesis that resveratrol has beneficial effects on AP.

Role of cytokines and microcirculatory dysfunction in acute pancreatitis
The transcription and nuclear factor kappa B (NF-kappa B) is an important substance of delivering intracellular signals[6-8]. It can modulate inflammatory procedures and immune reactions. It has already been proved that activation of NF-kappa B and NF-kappa B-mediated cytokine expression can act as one of the major factors for initiating and aggravating AP[9,10]. Furthermore, as an important inflammatory cell of AP, macrophage can release lots of cytokines that have multiple actions, overlap and synergize with each other. Those would make AP prone to develop from local disease to systemic inflammatory reaction syndrome (SIRS) and multiple organ system failure (MOSF)[11-13].

Microcirculatory dysfunction can induce AP as an initial factor and constant microcirculation dysfunction can aggravate pancreatic injury[14,15]. A lot of documents have suggested that the possible mechanism of microcirculatory dysfunction includes increased vascular permeability, reduced blood flow, leukocyte-endothelial cell interaction, ischemia/reperfusion injury, intravascular thrombus formation, and hypercoagulation[16-20]. The intervention in one or more of these processes can prevent at least partly the development of microcirculatory dysfunction in AP[21,22].

The pancreas is an organ highly susceptible to ischemic damage[23-25] and ischemia/reperfusion causes an inflammatory reaction in AP[26]. Several experimental studies have found that ischemia is associated to pancreatic injury. Ischemia/reperfusion injury is increasingly recognized as a common and important mechanism in the pathogenesis of AP and especially in the progression from mild edematous to severe necrotizing form[27].

Effect of resveratrol on the production of cytokines
Surh et al[28], showed that resveratrol could suppress the activation of NF-kappa B. Pellegratta et al[29], reported that the anti-inflammatory activity of resveratrol could be mediated by its interference with NF-kappa B dependent transcription. In this study, the influence of resveratrol (≤1 mmol/L) on the NF-kappa B signaling pathway after TNF-α stimulation of endothelial cells was observed. The result indicated that the long-term treatment of resveratrol could inhibit the nuclear appearance of NF-kxB in endothelial cells.
Besides, resveratrol can directly influence the production of macrophage function molecules (inhibiting the production of IL-6 and TNFα), which are all important inflammation medium in the development of AP.

**Effect of resveratrol on microcirculation**

Many studies have shown that resveratrol can affect the microcirculation of different organs by different mechanisms. They include the effects of resveratrol on NO production, aggregation of platelets, ischemic/reperfusion injury, and tissue factor (TF) expression.

Giovannini et al. has shown that preconditioning the hearts with resveratrol, provided cardioprotection as evidenced by improved postischemic ventricular functional recovery (developed pressure and aortic flow) and reduced myocardial infarct size. It was detected that resveratrol could induce the expression of inducible nitric oxide synthase (iNOS) mRNA beginning at 30 min after reperfusion and increasing steadily up to 60 min after reperfusion. The results suggested that resveratrol can precondition the heart in a nitric oxide (NO) dependent manner. Other studies investigated the effect of resveratrol on endothelial function in hypercholesterolemic rabbits. By measuring of plasma endothelia (ET-1) and NO levels, the researchers found that feeding a high cholesterol diet, significantly increased plasma ET-1 and decreased plasma NO concentration. With administration of resveratrol, plasma ET-1 levels statistically decreased, in parallel with a significant elevation in NO level.

Wallerath et al. suggested that resveratrol upregulated NOS mRNA expression in endothelial cells. NOS protein expression and NOS-derived production were also increased after long-term management of resveratrol. However, some trials drew the reverse conclusion, resveratrol regulating down the expression of NO.

By measuring platelet aggregation rate by Born's method, Wang et al. stated that aggregation of platelets in vitro by collagen (5 mg/mL), thrombin (0.33 units/mL), and ADP (4 mmol/L) was significantly inhibited by resveratrol in a concentration-dependent manner. Olas et al. showed the preincubation of washed platelets with resveratrol (25-100 mg/mL, 30 min, 37 °C), has an inhibitory effect on adhesion of platelet after being activated by LPS alone or LPS with thrombin and the strongest inhibitory effect was caused by resveratrol at the concentration of 100 mg/mL. They drew the conclusion that resveratrol may be an important compound responsible for the reduction of platelet adhesion and could change the reactivity of blood platelets in inflammatory process. The study of Suttnar et al., also supported that resveratrol has the capacity of inhibiting the aggregation response of washed platelet activated by collagen.

Shigematsu et al., reported that resveratrol prevents leukocyte recruitment and endothelial barrier disruption in the ischemic/reperfusion injury model in rat constructed by exposing mesenteries to 60 min reperfusion following 20 min ischemia and these effects may be related to the antioxidant properties of resveratrol. These results are consistent with that of other researches on heart, which supported that resveratrol has a beneficial effect on ischemia/reperfusion injury. Bradamante et al., proved that resveratrol can reduce ischemia/reperfusion injury in two time-related cardiac models and long-term moderate resveratrol consumption could play a more significant role in producing cardioprotective effects than short-term one. Moreover, as TF is a cell surface receptor for factor VII (a) and the binding of factor VII (a) to TF initiates, the coagulation cascade. Pendurthi et al., have shown that resveratrol inhibited the induction of TF expression in endothelial cells and mononuclear cells.

**Therapeutic effect of resveratrol on AP**

Due to its strong effect of inhibiting activation of NF-kappa B and reducing secondary activation of cytokines, resveratrol is regarded as a promising drug of blocking the initiation and progress of AP. However, the current trial has only proved the inhibiting effect of resveratrol on NF-kappa B from cellular level, its mechanism needs be illustrated with further studies.

Though NO function in AP is still obscure and has disagreements in the public, many scholars think that NO may have a beneficial influence on the capillary organ perfusions, reduce release of amylase and prevent the development of AP. As resveratrol may induce the production of NO, it is possible for resveratrol to improve the capillary organ perfusion in AP.

Pancreatic capillary endothelial barrier dysfunction is an initial and characteristic feature of acute pancreatic injury and pancreatitis, it is related to hypercoagulation, increased vascular permeability and leukocyte adhesion. It is partly manifested by increased platelet adhesion and aggregation. Resveratrol can inhibit platelet aggregation both in vitro and in vivo and enhance the integrity of endothelium in atherosclerosis and cardiovascular disease and significantly prevented the cytokine-induced vascular leakage, so it is also possible for resveratrol to prevent the injury of vascular endothelium in AP and reduce the extent of blood coagulation.

**DISCUSSION**

Following the deep recognition of the pathogenesis in AP, there have been recently many changes in the management of AP. Pure medical measures and surgical treatment have reverted to comprehensive management and operation should be performed only when there is a secondary infection. However, the current mortality of AP is still very high, and new measures are strongly needed.

Many new drugs have appeared as effective methods in managing AP and most of them exert therapeutic effects through different pathways. Being extracted from plants, resveratrol is proved to have various pharmacologic activations (anti-inflammatory, antioxidation, chemopreventive effects and inhibition of platelet aggregation). It has already been regarded as an effective medical drug on the management of arteriosclerosis, cardiac disease and tumor. Though there is still no document to illustrate the function of resveratrol in AP, we can draw the conclusion from upper arguments that resveratrol can have some effects in the management of acute pancreatitis by inhibiting the activation of cytokines.
and in improving microcirculation. The primary trial in our laboratory has found that resveratrol could inhibit the production of TNF and IL-6 in pancreatitis, but more researches still need to be performed. Furthermore, its toxicity and pharmacokinetics should be studied further.

REFERENCES

1. Chase CW, Barker DE, Russell WL, Burns RP. Serum amylase and lipase in the evaluation of acute abdominal pain. *Am Surg* 1996; 62: 1028-1033
2. Shen F, Chen SJ, Dong XJ, Zhong H, Li YT, Cheng GF. Suppression of IL-8 gene transcription by resveratrol in phorbol ester treated human mononcytic cells. *J Asian Nat Prod Res* 2003; 5: 151-157
3. Olas B, Wachowicz B. Biological activity of resveratrol. *Postepy Hig Med Dosw* 2001; 55: 71-79
4. Bhat KPL JW, Pezzuto JM. Biological effects of resveratrol. *Antioxid Redox Signal* 2001; 3: 1041-1064
5. Bao Lin, Inami Y, Tanaka H, Inagaki N, Linuma M, Nagai H. Resveratrol inhibits the release of mediators from bone marrow-derived mouse mast cells in vitro. *Planta Med* 2004; 70: 305-309
6. Altavilla D, Famulari C, Passanti M, Galeano M, Macri A, Seminara P, Minutoli L, Marini H, Calo M, Venuti FS, Esposito M, Squadrito F. Attenuated cerulein-induced pancreatitis in nuclear factor-kappaB-deficient mice. *Lab Invest* 2003; 83: 1723-1732
7. Liu HS, Fan CE, Liu QQ, Yang W, Liu XM. Effect of NF-kappaB and p38 MAPK in activated monocytes/macrophages on pro-inflammatory cytokines of rats with acute pancreatitis. *World J Gastroenterol* 2003; 9: 2513-2518
8. Algul H, Tando Y, Schneider G, Weidenbach H, Adler G, Schmid RM. Acute experimental pancreatitis and NF-kappaB/Rel activation. *Pancreatology* 2002; 2: 503-509
9. Chen X, Ji B, Han B, Ernst SA, Simeone D, Logsdon CD. NF-kappaB activation in pancreas induces pancreatic and systemic inflammatory response. *Gastroenterology* 2002; 122: 448-457
10. Seo JY, Kim H, Seo JT, Kim KH. Oxidative stress induced cytokine production in isolated rat pancreatic acinar cells: effects of small-molecule antioxidants. *Pharmacology* 2002; 64: 63-70
11. Mikami Y, Takeda K, Shibuya K, Qiu-Feng H, Shimamura H, Yamauchi J, Egawa S, Suminura M, Yagi H, Endo Y, Matsuno S. Do peritoneal macrophages play an essential role in the progression of acute pancreatitis? *Rats Pancreas* 2003; 27: 253-260
12. Demydov VM, Zaporozhchenko BS, Demidov SM. Changes of cytokine levels in the serum in patients with acute pancreatitis as an early symptom for diagnosis. *Kim Khir* 2003; 3: 29-32
13. Sakai Y, Masamune A, Satoh A, Nishihira J, Yamagita W, Shimosegawa T. Macrophage migration inhibitory factor is a critical mediator of severe acute pancreatitis. *Gastroenterology* 2003; 124: 725-736
14. Schmidt J, Ebeling D, Ryschich E, Werner J, Gebhard MM, Klar E. Pancreatic capillary blood flow in an improved model of necrotizing pancreatitis in the rat. *J Surg Res* 2002; 106: 335-341
15. Dobosz M, Hac S, Mioskowska L, Dobrowolski S, Wajda Z. Microcirculatory disturbances of the pancreas in cerulein-induced acute pancreatitis in rats with reference to L-arginine, heparin, and procaine treatment. *Pharmacol Res* 1997; 36: 123-128
16. Gao HK, Zhou ZG, He T, Chen YQ, Han FH, Wang C. Effects of TCM-1 on the changes of platelet endothelial cell adhesion molecule-1 expression in acute edematous pancreatitis. *Hepatobiliary Pancreat Dis Int* 2004; 3: 311-315
17. Hackert T, Werner J, Gebhard MM, Klar E. Effects of heparin in experimental models of acute pancreatitis and post-ERCP pancreatitis. *Surgery* 2004; 135: 131-138
18. Kaska M, Pospisilova B, Slizova D. Pathomorphological changes in microcirculation of pancreas during experimental acute pancreatitis. *Hepatogastroenterology* 2000; 47: 1570-1574
19. Sunamura M, Shibuya K, Yamauchi J, Matsuno S. Microcirculatory derangement and ischemia of the pancreas. *Nihon Geka Gakkai Zasshi* 1999; 100: 342-346
20. Schmidt J, Klar E. Etiology and pathophysiology of acute pancreatitis. *Ther Umsch* 1996; 53: 322-332
21. von Dobschuetz E, Bleiziffer O, Papernik S, Dellian M, Hofmann T, Messmer K. Soluble complement receptor 1 preserves endothelial barrier function and microcirculation in postischemic pancreatitis in the rat. *Am J Physiol Gastrointest Liver Physiol* 2004; 286: G791-G796
22. Werner J, Hartwig W, Schmidt E, Gebhard MM, Herfarth C, Klar E. Reduction of local and systemic complications of acute pancreatitis by monoclonal antibody to ICAM-1. *Langenbecks Arch Chir Suppl Kongressbd* 1999; 115: 725-729
23. Obermaier R, Benz S, Kortmann B, Benthues A, Ansorge N, Hopt UT. Ischemia/reperfusion-induced pancreatitis in rats: a new model of complete normothermic in situ ischemia of a pancreatic tail-segment. *Clin Exp Med* 2001; 1: 51-59
24. Sakorafas GH, Tsiotou GG, Sarr MG. Ischemia/Reperfusion-Induced pancreatitis. *Dig Surg* 2000; 17: 3-14
25. Hoffmann TF, Reiderer R, Harris AG, Messmer K. Ischemia and reperfusion in pancreas. *Microsc Res Tech* 1997; 37: 557-571
26. Hoffmann TF, Reiderer R, Waldner H, Arbogast S, Messmer K. Ischemia reperfusion of the pancreas: a new in vivo model for acute pancreatitis in rats. *Res Exp Med (Berl)* 1995; 195: 125-144
27. Sakorafas GH, Tsiotou AG. Etiology and pathogenesis of acute pancreatitis: current concepts. *J Clin Gastroenterol* 2000; 30: 343-356
28. Suri YJ, Chun KS, Cha HH, Han SS, Kyes UM, Park KK, Lee SS. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. *Matat Res 2001; 408:481-484:268*
29. Pellegratta F, Bertelli AA, Staels B, Duhem C, Fulgenzi A, Ferrore ME. Different short- and long-term effects of resveratrol on nuclear factor-kappaB phosphorylation and nuclear appearance in human endothelial cells. *Am J Clin Nutr* 2003; 77: 1220-1228
30. Culpitt SV, Rogers DF, Fenwick PS, Shah P, De Matos C, Russell RE, Barnes PJ, Donnelly LE. Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. *Thorax* 2003; 58: 942-946
31. Zhong M, Cheng GF, Wang WJ, Guo Y, Zhu XY, Zhang JT. Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice. *Phytomedicine* 1999; 6: 79-84
32. Feng YH, Zou JP, Li XY. Effects of resveratrol and ethanol on production of pro-inflammatory factors from endotoxin activated murine macrophages. *Acta Pharmacol Sin* 2002; 23: 1002-1006
33. Hattori R, Otani H, Maulik N, Das DK. Pharmacological preconditioning with resveratrol: role of nitric oxide. *Am J Physiol Heart Circ Physiol* 2002; 282: H1988-H1995
34. Zou JG, Wang ZR, Huang YZ, Cao KJ, Wu JM. Effect of red wine and wine polyphenol resveratrol on endothelial function in hypercholesterolemic rabbits. *Int J Mol Med* 2003; 11: 317-320
35. Wallerath T, Deckert G, Ternes A, Anderson H, Li H, Witte K, Forstermann U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. *Circulation* 2002; 106: 1652-1658
36. Tsai SL, Lin-Shiau SY, Lin JK. Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. *Br J Pharmacol* 1999; 126: 673-680
37. Roman V, Billard C, Kern C, Ferry-Dumazet H, Izard JC,
Mohammad R, Mossalayi DM, Kolb JP. Analysis of resveratrol-induced apoptosis in human B-cell chronic leukaemia. Br J Haematol 2002; 117: 842-851

Wang Z, Huang Y, Zou J, Cao K, Xu Y, Wu JM. Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int J Mol Med 2002; 9: 77-79

Olas B, Wachowicz B, Saluk-Juszczak J, Zielinski T. Effect of resveratrol, a natural polyphenolic compound, on platelet activation induced by endotoxin or thrombin. Thromb Res 2002; 107: 141-145

Suttnar J, Masova L, Scheiner T, Sorelova V, Dyr JE. Role of free radicals in blood platelet activation. Cas Lek Cesk 2002; 141 Suppl: 47-49

Shigematsu S, Ishida S, Hara M, Takahashi N, Yoshimatsu H, Sakata T, Korthuis RJ. Resveratrol, a red wine constituent polyphenol, prevents superoxide-dependent inflammatory responses induced by ischemia/reperfusion, platelet-activating factor, or oxidants. Free Radic Biol Med 2003; 34: 810-817

Hung LM, Su MJ, Chen JK. Resveratrol protects myocardial ischemia-reperfusion injury through both NO-dependent and NO-independent mechanisms. Free Radic Biol Med 2004; 36: 774-781

de Lorgeril M, Salen P, Guiraud A, Boucher F, de Leiris J. Resveratrol and non-ethanolic components of wine in experimental cardiology. Nutr Metab Cardiovasc Dis 2003; 13: 100-103

Cui J, Tosaki A, Bertelli AA, Bertelli A, Maulik N, Das DK. Cardioprotection with white wine. Drugs Exp Clin Res 2002; 28: 1-10

Hung LM, Chen JK, Lee RS, Liang HC, Su MJ. Beneficial effects of astringin, a resveratrol analogue, on the ischemia and reperfusion damage in rat heart. Free Radic Biol Med 2001; 30: 877-883

Bradamante S, Baronghi L, Piccinini F, Bertelli AA, De Jonge R, Beemster P, De Jong JW. Resveratrol provides late-phase cardioprotection by means of a nitric oxide- and adenosine-mediated mechanism. Eur J Pharmacol 2003; 465: 115-123

Pendurthi UR, Meng F, Mackman N, Rao LV. Mechanism of resveratrol-mediated suppression of tissue factor gene expression. Thromb Haemost 2002; 87: 155-162

DiMaggio MJ, Williams JA, Hao Y, Ernst SA, Owyang C. Endothelial nitric oxide synthase is protective in the initiation of caerulein-induced acute pancreatitis in mice. Am J Physiol Gastrointest Liver Physiol 2004; 287: G80-G87

Zhang Z, Sun J, Li F, Zhang S, Cui Y, Sun H, Liu S. Protective effect of nitric oxide on pancreas and its relation to sulfhydryl compounds and oxygen free radicals. Zhonghua Waike Za Zhi 2000; 38: 928-930

Dobosz M, Hac S, Wajda Z. Does nitric oxide protect from microvascular disturbances in experimental acute pancreatitis in rats? Int J Microcirc Clin Exp 1996; 16: 221-226

Taubert D, Berkels R. Upregulation and activation of eNOS by resveratrol. Circulation 2003; 107: e78-e79; author reply e78-e79

Vergara M, Modolell I, Puig-Divi V, Guarnier L, Malagelada JR. Acute pancreatitis as a triggering factor for thrombotic thrombocytopenic purpura. Am J Gastroenterol 1998; 93: 2215-2218

Wang Z, Zou J, Huang Y, Cao K, Xu Y, Wu JM. Effect of resveratrol on platelet aggregation in vivo and in vitro. Chin Med J (Engl) 2002; 115: 378-380

Huang SS, Tsai MC, Chih CL, Hung LM, Tsai SK. Resveratrol reduction of infarct size in Long-Evans rats subjected to focal cerebral ischemia. Life Sci 2001; 69: 1057-1065

Slater SJ, Seiz JL, Cook AC, Stagliano BA, Buzas CJ. Inhibition of protein kinase C by resveratrol. Biochim Biophys Acta 2003; 1637: 59-69

Bertelli AA, Baccalini R, Battaglia E, Falchi M, Ferrero ME. Resveratrol inhibits TNF alpha-induced endothelial cell activation. Therapie 2001; 56: 613-616

Mitchell RM, Byrne MF, Baillie J. Pancreatitis. Lancet 2003; 361: 1447-1455

Youssaf M, McCallion K, Diamond T. Management of severe acute pancreatitis. Br J Surg 2003; 90: 407-420